Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Viracta Therapeutics, Inc. | snss-ex312_7.htm |
| EX-31.1 - EX-31.1 - Viracta Therapeutics, Inc. | snss-ex311_8.htm |
| 10-Q - Q3 2018 10-Q - Viracta Therapeutics, Inc. | snss-10q_20180930.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dayton Misfeldt, Interim Chief Executive Officer and William P. Quinn, Senior Vice President, Finance and Corporate Development and Chief Financial Officer, of Sunesis Pharmaceuticals, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:
|
1. |
The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2018 (the “Periodic Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
|
2. |
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: November 5, 2018 |
|
/s/ DAYTON MISFELDT |
|
|
|
Dayton Misfeldt Interim Chief Executive Officer |
|
|
|
|
|
Date: November 5, 2018 |
|
/s/ WILLIAM P. QUINN |
|
|
|
William P. Quinn Senior Vice President, Finance and Corporate Development, Chief Financial Officer |
|
|
|
|
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.